#cipla
Buzzing stocks: Hero MotoCorp, Lenskart, Cipla, Wipro, Tejas Networks and more
From a major Ather investment and Lenskart’s block deal to fresh orders for Tejas Networks, NBCC and Skipper, several stocks are in focus today. Cipla, Wipro, RPP Infra and other companies also bring key corporate developments to investors’ radar
IT selloff drags Nifty below 24,000; pharma stocks buck the trend
Pharma bucked the broader trend and remained the standout performer of the session. Cipla led gains on the Nifty 50, rising 2.56 per cent to ₹1,452 with over 37.20 lakh shares traded worth ₹53,831.39 lakh
Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?
Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla's performance remain…
Cipla looks to ensure consistent drug supplies, as costs increase due to West Asia war, says MD & Global CEO
The company’s net profit at Rs ₹555 crore for the quarter under review was down 55 per cent from Rs ₹1,222 crore in the same period last year
Cipla looks to ensure consistent drug supplies, as costs increase due to West Asia war, says MD & Global CEO
The company’s net profit at Rs ₹555 crore for the quarter under review was down 55 per cent from Rs ₹1,222 crore in the same period last year
Cipla bets on fast-growing biosimilars market, to steadily add products: CEO
Cipla is developing a biosimilars pipeline, with plans to add 1-2 products yearly for the next five years. The drugmaker is investing in R&D, especially for developed markets, to build out a strong pipeline across respiratory, peptides as well as complex …